All In Biotech

Drug Trial Radar · NCT06004050

A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema

A Phase 3 Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Twice-Daily Applications of Delgocitinib Cream 20 mg/g in Chinese Adults and Adolescents (12-17 Years of Age) With Moderate to Severe Chronic Hand Eczema

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

362

Actual

Start

Sep 5, 2023

Primary completion

Dec 16, 2024

Study completion Sep 12, 2025

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of twice-daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of participants with moderate to severe chronic hand eczema (CHE).

Conditions

  • Chronic Hand Eczema

Interventions

  • DelgocitinibDrug

    Topical administration

  • Vehicle creamOther

    Topical administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator Global Assessment for Chronic Hand Eczema Score (IGA-CHE TS) at Week 16Time frame: Week 16

Locations

37 sites in 1 country. Site status is shown where the registry gives one.

  • LEO Pharma Investigational Site

    Beijing, China

  • LEO Pharma Investigational Site

    Beijing, China

  • LEO Pharma Investigational Site

    Beijing, China

  • LEO Pharma Investigational Site

    Beijing, China

  • LEO Pharma Investigational Site

    Changchun, China

  • LEO Pharma Investigational Site

    Changsha, China

  • LEO Pharma Investigational Site

    Changsha, China

  • LEO Pharma Investigational Site

    Changzhou, China

  • LEO Pharma Investigational Site

    Chengdu, China

  • LEO Pharma Investigational Site

    Chengdu, China

  • LEO Pharma Investigational Site

    Fuzhou, China

  • LEO Pharma Investigational Site

    Guangzhou, China

  • LEO Pharma Investigational Site

    Guangzhou, China

  • LEO Pharma Investigational Site

    Guiyang, China

  • LEO Pharma Investigational Site

    Hangzhou, China

  • LEO Pharma Investigational Site

    Hangzhou, China

  • LEO Pharma Investigational Site

    Hangzhou, China

  • LEO Pharma Investigational Site

    Hefei, China

  • LEO Pharma Investigational Site

    Nanchang, China

  • LEO Pharma Investigational Site

    Nanjing, China

  • LEO Pharma Investigational Site

    Nanyang, China

  • LEO Pharma Investigational Site

    Shanghai, China

  • LEO Pharma Investigational Site

    Shenyang, China

  • LEO Pharma Investigational Site

    Shenzhen, China

  • LEO Pharma Investigational Site

    Shenzhen, China

  • LEO Pharma Investigational Site

    Shenzhen, China

  • LEO Pharma Investigational Site

    Shenzhen, China

  • LEO Pharma Investigational Site

    Shijiazhuang, China

  • LEO Pharma Investigational Site

    Wenzhou, China

  • LEO Pharma Investigational Site

    Wuhan, China

  • LEO Pharma Investigational Site

    Wuhan, China

  • LEO Pharma Investigational Site

    Wuhan, China

  • LEO Pharma Investigational Site

    Wuxi, China

  • LEO Pharma Investigational Site

    Xianyang, China

  • LEO Pharma Investigational Site

    Yinchuan, China

  • LEO Pharma Investigational Site

    Yiwu, China

  • LEO Pharma Investigational Site

    Zhenjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.